Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Efficacy and safety of linagliptin in persons with Type-2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

Owens, David Raymond, Swallow, R., Dugi, K. A. and Woerle, H. J. 2011. Efficacy and safety of linagliptin in persons with Type-2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1. Diabetic Medicine 28 (11) , pp. 1352-1361. 10.1111/j.1464-5491.2011.03387.x

Full text not available from this repository.

Abstract

Aims To examine the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled [HbA1c 53–86 mmol/mol (7.0–10.0%)] by metformin and sulphonylurea combination treatment. Methods A multi-centre, 24-week, randomized, double-blind, parallel-group study in 1058 patients comparing linagliptin (5 mg once daily) and placebo when added to metformin plus sulphonylurea. The primary endpoint was the change in HbA1c after 24 weeks. Results At week 24, the linagliptin placebo-corrected HbA1c adjusted mean change from baseline was −7 mmol/mol (−0.62%) [95% CI −8 to −6 mmol/mol (−0.73 to −0.50%); P < 0.0001]. More participants with baseline HbA1c≥ 53 mmol/mol (≥ 7.0%) achieved an HbA1c < 53 mmol/mol (< 7.0%) with linagliptin compared with placebo (29.2% vs. 8.1%, P < 0.0001). Fasting plasma glucose was reduced with linagliptin relative to placebo (−0.7 mmol/l, 95% CI −1.0 to −0.4; P < 0.0001). Improvements in homeostasis model assessment of β-cell function were seen with linagliptin (P < 0.001). The proportion of patients who reported a severe adverse event was low in both groups (linagliptin 2.4%; placebo 1.5%). Symptomatic hypoglycaemia occurred in 16.7 and 10.3% of the linagliptin and placebo groups, respectively. Hypoglycaemia was generally mild or moderate; severe hypoglycaemia was reported in 2.7 and 4.8% of the participants experiencing hypoglycaemic episodes in the linagliptin and placebo groups, respectively. No significant weight changes were noted. Conclusions In patients with Type 2 diabetes, adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated. Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: dipeptidyl peptidase-4 inhibitor, linagliptin, metformin, sulphonylurea, Type 2 diabetes
Publisher: Wiley
ISSN: 0742-3071
Last Modified: 04 Jun 2017 03:48
URI: http://orca.cf.ac.uk/id/eprint/27109

Citation Data

Cited 171 times in Google Scholar. View in Google Scholar

Cited 192 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item